SRF Limited’s Board of Directors has approved the establishment of a New Pharma Intermediate Plant (PIP-2) with a projected cost of ₹180 Crores. This decision, made on January 20, 2026, aims to support the production of pharma products at the company’s Dahej, Gujarat facility. The investment will be funded through a mix of debt and internal accruals, capitalizing on emerging business opportunities in the pharmaceutical sector.
New Pharma Plant Project
SRF Limited is set to expand its manufacturing capabilities with a new Pharma Intermediate Plant (PIP-2). Approved on January 20, 2026, this project represents a significant investment in the company’s pharmaceutical segment.
Investment and Funding
The project is estimated to cost ₹180 Crores. The funding will be sourced through a combination of debt and internal accruals, ensuring a balanced approach to financing this expansion.
Strategic Rationale
This investment is driven by the objective to tap into new and upcoming business opportunities within the pharma space. SRF Limited aims to strengthen its position in the pharmaceutical market by increasing its production capacity of precursor processes.
Projected Completion
The company anticipates the proposed capacity to be added by September 30, 2026, marking a key milestone in SRF Limited’s growth strategy.
Source: BSE
